In advanced luminal breast cancer, CDK4/6 inhibitors demonstrated a remarkable improvement in PFS and OS, and recently, the biomarkers PIK3CA and BRCA have defined a new strategy of treatment. Here, CDK4 is linked to breast carcinoma.